• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

桂利嗪治疗慢性哮喘

Cinnarizine in the treatment of chronic asthma.

作者信息

Emanuel M B, Chamberlain J A, Whiting S, Rigden B G, Craven A H

出版信息

Br J Clin Pharmacol. 1979 Feb;7(2):189-95. doi: 10.1111/j.1365-2125.1979.tb00920.x.

DOI:10.1111/j.1365-2125.1979.tb00920.x
PMID:367414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1429430/
Abstract

1 Cinnarizine, an inhibitor of calcium ion transport across smooth muscle cell membrane, has been shown to exert an anti-asthmatic effect in patients with chronic asthma. 2 It is postulated that antagonism to calcium ion transport across the mast cell membrane may cause the compound to have a pharmacological effect similar to sodium cromoglycate. 3 Cinnarizine is orally active and its therapeutic effect is demonstrated in a double-blind, cross-over, placebo controlled study. 4 Patient benefit was shown by a significant improvement in peak flow rate. A non-significant trend towards a reduction in symptomatic bronchodilator usage and a decrease in asthma symptom score was also shown. 5 It is concluded that cinnarizine could well prove to be the first of a new family of anti-asthmatic drugs offering a protective effect when taken systemically.

摘要
  1. 桂利嗪是一种抑制钙离子跨平滑肌细胞膜转运的药物,已被证明对慢性哮喘患者有抗哮喘作用。2. 据推测,拮抗钙离子跨肥大细胞膜的转运可能使该化合物具有与色甘酸钠相似的药理作用。3. 桂利嗪口服有效,其治疗效果在一项双盲、交叉、安慰剂对照研究中得到证实。4. 峰值流速显著改善表明患者受益。同时还显示出症状性支气管扩张剂使用减少和哮喘症状评分降低的非显著趋势。5. 得出的结论是,桂利嗪很可能被证明是一类新型抗哮喘药物中的第一种,全身服用时具有保护作用。

相似文献

1
Cinnarizine in the treatment of chronic asthma.桂利嗪治疗慢性哮喘
Br J Clin Pharmacol. 1979 Feb;7(2):189-95. doi: 10.1111/j.1365-2125.1979.tb00920.x.
2
A double-blind placebo controlled study of cinnarizine in the prophylaxis of seasickness.桂利嗪预防晕船的双盲安慰剂对照研究。
Practitioner. 1980 May;224(1343):547-50.
3
Treatment of chronic urticaria with an inhibitor of complement activation (cinnarizine).
Ann Allergy. 1980 Jan;44(1):34-7.
4
A multicentre general practice study of cinnarizine in the treatment of peripheral vascular disease.桂利嗪治疗周围血管疾病的多中心全科医学研究。
J Int Med Res. 1979;7(6):502-6. doi: 10.1177/030006057900700604.
5
Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation.氟桂利嗪预防典型偏头痛的安慰剂对照评估。
Cephalalgia. 1985 Mar;5(1):31-7. doi: 10.1046/j.1468-2982.1985.0501031.x.
6
Intermittent claudication: a controlled study in parallel time of the short-term and long-term effects of cinnarizine.
Pharmatherapeutica. 1980;2(6):401-7.
7
[Clinical trial of cinnarizine in some vascular diseases].桂利嗪治疗某些血管疾病的临床试验
Rev Med Chir Soc Med Nat Iasi. 1976 Jan-Mar;80(1):19-22.
8
Therapy of chronic consequences of brain ischemia. Comparison between two drugs acting on brain circulation and metabolism.脑缺血慢性后果的治疗。两种作用于脑循环和代谢的药物之间的比较。
Eur Neurol. 1978;17 Suppl 1:150-8. doi: 10.1159/000115019.
9
Double-blind placebo-controlled studies with flunarizine in venous insufficiency.氟桂利嗪用于静脉功能不全的双盲安慰剂对照研究。
Angiology. 1980 Dec;31(12):833-45. doi: 10.1177/000331978003101204.
10
Oxatomide in seasonal rhinoconjunctivitis.
Allergy. 1980 Jun;35(4):319-22. doi: 10.1111/j.1398-9995.1980.tb01773.x.

引用本文的文献

1
Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach.桂利嗪给药系统与治疗方法的最新进展:一种胃内有吸收窗的难溶性药物
J Drug Deliv. 2014;2014:479246. doi: 10.1155/2014/479246. Epub 2014 Nov 13.
2
Efficacy of calcium channel blockers as maintenance therapy for asthma.钙通道阻滞剂作为哮喘维持治疗的疗效。
Br J Clin Pharmacol. 2002 Mar;53(3):243-9. doi: 10.1046/j.0306-5251.2001.01560.x.
3
Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma.硝苯地平对哮喘患者支气管运动张力和组胺反应性的影响。
Br Med J (Clin Res Ed). 1981 Aug 1;283(6287):348. doi: 10.1136/bmj.283.6287.348.
4
Calcium channel blockers and asthma.钙通道阻滞剂与哮喘
Lung. 1986;164(1):1-16. doi: 10.1007/BF02713625.

本文引用的文献

1
Cinnarizine in the treatment of peripheral vascular disease: mechanisms related to its clinical action.桂利嗪治疗外周血管疾病:与其临床作用相关的机制
Proc R Soc Med. 1977;70(Suppl 8):7-12. doi: 10.1177/00359157770700S802.
2
Further observations on the disruption of rat mesentery mast cells caused by compound 48/80, antigen-antibody reaction, lecithinase A and decylamine.关于化合物48/80、抗原-抗体反应、卵磷脂酶A和癸胺对大鼠肠系膜肥大细胞破坏作用的进一步观察
Acta Physiol Scand. 1960 Mar 18;48:133-45. doi: 10.1111/j.1748-1716.1960.tb01853.x.
3
EFFECTS OF COMPOUND 48/80, CHYMOTRYPSIN AND ANTI-SERUM ON ISOLATED MAST CELLS UNDER AEROBIC AND ANAEROBIC CONDITIONS.化合物48/80、胰凝乳蛋白酶和抗血清在需氧和厌氧条件下对分离的肥大细胞的作用。
Jpn J Pharmacol. 1964 Sep;14:375-90. doi: 10.1254/jjp.14.375.
4
EXPIRATORY PEAK FLOW RATE. STANDARD VALUES FOR NORMAL SUBJECTS. USE AS A CLINICAL TEST OF VENTILATORY FUNCTION.呼气峰值流速。正常受试者的标准值。用作通气功能的临床检测指标。
Am Rev Respir Dis. 1963 Nov;88:644-51. doi: 10.1164/arrd.1963.88.5.644.
5
Human bioassay of antihistaminic agents.抗组胺药的人体生物测定
Ann Allergy. 1962 Jan;20:37-44.
6
Maximum forced expiratory flow rate as a measure of ventilatory capacity: with a description of a new portable instrument for measuring it.作为通气能力指标的最大用力呼气流量率:并介绍一种测量该指标的新型便携式仪器。
Br Med J. 1959 Nov 21;2(5159):1041-6. doi: 10.1136/bmj.2.5159.1041.
7
Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms.色甘酸钠(FPL 670)(“因他舒”):一种反应素抗体-抗原机制的特异性抑制剂。
Nature. 1967 Dec 30;216(5122):1328-9. doi: 10.1038/2161328a0.
8
Therapeutic and investiational evaluation of asthmatic children.
J Allergy. 1968 Jan;41(1):23-36. doi: 10.1016/0021-8707(68)90005-1.
9
Mast cells and allergic asthma.肥大细胞与过敏性哮喘。
Br J Dis Chest. 1973 Apr;67(2):87-106. doi: 10.1016/0007-0971(73)90037-5.
10
Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use.色甘酸钠:其作用机制、药理学、治疗效果及应用综述
Drugs. 1974;7(3):164-282. doi: 10.2165/00003495-197407030-00002.